Bellerophon's stock tanks as in­haled drug-de­vice fails to re­deem it­self in new PhI­II af­ter pre­vi­ous flops

3 years ago
R&D

Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

3 years ago
R&D

FDA lifts clin­i­cal hold on Foghorn’s study for blood and bone mar­row can­cer treat­ment

3 years ago
R&D

Es­cap­ing an im­prob­a­ble up­bring­ing, Greg Ver­dine places his biggest ca­reer bets in drug­ging the ‘un­drug­gable’

3 years ago
People
In Focus

As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

3 years ago
R&D

Mod­er­na, Mer­ck say their can­cer vac­cine re­duces metas­tases by 65% in PhII study of high-risk melanoma: #AS­CO23

3 years ago
R&D

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

3 years ago
R&D
Cell/Gene Tx

J&J’s blad­der can­cer drug Balver­sa cuts the risk of death in fol­low-up tri­al: #AS­CO23

3 years ago
R&D

No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

3 years ago
Deals

How you ac­cess End­points News is chang­ing

3 years ago
Editor's note

As­traZeneca moves ear­ly for full ap­proval with an­ti­co­ag­u­lant re­ver­sal drug An­dexxa af­ter pos­i­tive PhIV da­ta

3 years ago
R&D
FDA+

Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

3 years ago
R&D

Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

3 years ago
R&D

As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

3 years ago
R&D

Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

3 years ago
R&D

Keytru­da be­fore and af­ter lung can­cer surgery cuts re­lapse risk by 42%, but doesn’t im­prove sur­vival: #AS­CO23

3 years ago
R&D

Roger Perl­mut­ter lines up deals, fresh fund­ing at Eikon; Sec­ond RSV vac­cine ap­proved; Sev­er­al biotechs flash­ing red; ...

3 years ago
Weekly

Grail’s blood test charts path for di­ag­nos­ing pa­tients sus­pect­ed of hav­ing can­cer in large study: #AS­CO23

3 years ago
R&D

Cana­di­an CD­MO se­cures more fund­ing to get its man­u­fac­tur­ing site up and run­ning

3 years ago
Financing
Manufacturing

NICE rec­om­mends Bris­tol My­er­s' heart drug Camzyos in UK

3 years ago
Pharma

GSK pro­motes rou­tine im­mu­niza­tions for adults amid post-pan­dem­ic vac­cine back­slide

3 years ago
Pharma
Marketing

Gilead joins Tik­Tok with on­col­o­gy aware­ness cam­paign fea­tur­ing di­verse group of can­cer ad­vo­cates

3 years ago
Pharma
Marketing

No­vo Nordisk wins age bias suit with the EEOC in New Jer­sey fed­er­al court

3 years ago
Pharma
Law

3M to make $146M in­vest­ment in­to pro­duc­ing bio­phar­ma tech­nol­o­gy

3 years ago
Manufacturing
First page Previous page 332333334335336337338 Next page Last page
A service from the Financial Times